Call for high impact clinical trials in pancreatic and biliary tract cancer (RFA PDAC)Funder(s): Anticancer Fund, Rising Tide Foundation for Clinical Cancer Research,
We are seeking to support clinical trials testing novel and unique strategies in the treatment of patients diagnosed with pancreatic ductal adenocarcinomas (PDAC) and/or biliary tract cancer (BTC)*. The proposal needs to have the potential to have a high impact (e.g. improve cure rate or survival) on the treatment of these cancers.
We are looking for innovative approaches extrapolated from laboratory work in relevant cancer models or extrapolated from other cancer types but deemed applicable in PDAC and/or BTC. Both early phase trials as later phase trials with an out-of-the-box concept are permitted. In principal, generating proof-of concept data or exploring novel promising interventions not investigated yet or building on preliminary pilot data are welcomed. Proposals might not be deemed innovative if the intervention is being or has been investigated by other groups or if there is only a small incremental gain in knowledge and/or outcome.
Timeline & Milestones
April 30, 2021
Deadline First stage (LOI / pre-proposal)
June 30, 2021
Announcement of Applicants selected for stage 2
August 16, 2021
Deadline Full Application
October 17, 2021
Grant Decision – Final Decision – Awarding
December 20, 2021